Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,082 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vision Disorder Clear all
Completed Not applicable Interventional

Effects of a Single OMT on Intraocular Pressure (IOP) in Ocular Hypertenive or Glaucoma Suspect Subjects

NCT01864642
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
osteopathic manipulative treatment (OMT)
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 28, 2026, 8:28 AM EDT
Withdrawn Phase 4 Interventional

A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension

NCT04140279
View directory record Official record
Conditions
Ocular Hypertension
Interventions
Latanoprostene Bunod, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 28, 2026, 8:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia

NCT05656027
View directory record Official record
Conditions
Presbyopia, Refractive Error, Eye Diseases, Near Vision
Interventions
Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Brimonidine
Drug
Lead sponsor
LENZ Therapeutics, Inc
Other
Eligibility
45 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
25
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 28, 2026, 8:28 AM EDT
Not yet recruiting Phase 4 Interventional

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

NCT07048886
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Rocklatan (netarsudil 0.02% and latanoprost 0.005%), Systane
Drug
Lead sponsor
Center for Sight Las Vegas
Other
Eligibility
40 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 28, 2026, 8:28 AM EDT
Withdrawn Phase 4 Interventional

Manuka Eye Droops for Treatment of Allergy

NCT03862053
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Manuka honey
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Germantown, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 28, 2026, 8:28 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease

NCT01254370
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Ocular Surface Disease
Interventions
Latanoprost, Travatan Z
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 28, 2026, 8:28 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

NCT07465289
View directory record Official record
Conditions
Ocular Myasthenia Gravis
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 8:28 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain

NCT07348276
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP), Healthy Participants
Interventions
[18F]ABBV-964i, [18F]ABBV-965i, Lead Candidate
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 28, 2026, 8:28 AM EDT
Completed Not applicable Interventional Results available

Performance Assessment of a Modified Daily Disposable Contact Lens

NCT03762668
View directory record Official record
Conditions
Refractive Errors, Myopia, Hyperopia
Interventions
Modified delefilcon A contact lenses, Delefilcon A contact lenses
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Maitland, Florida • Orlando, Florida • West Palm Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 28, 2026, 8:28 AM EDT
Not listed No phase listed Observational

Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women

NCT03767803
View directory record Official record
Conditions
Pre-Eclampsia, Hypertension, Proteinuria in Pregnancy, Thrombocytopenia, Renal Insufficiency, Impaired Liver Function, Pulmonary Edema, Headache, Visual Impairment
Interventions
Non-interventional study
Other
Lead sponsor
Progenity, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
San Diego, California • Newark, Delaware • Boca Raton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 28, 2026, 8:28 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

NCT03691662
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
12 Months and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
34
States / cities
Chandler, Arizona • Prescott, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 28, 2026, 8:28 AM EDT
Completed Phase 2 Interventional

Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis

NCT00070759
View directory record Official record
Conditions
Uveitis
Interventions
Daclizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 8:28 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

NCT05127525
View directory record Official record
Conditions
Diabetic Macular Edema, Branch Retinal Vein Occlusion, Glaucoma/Closed Angle Glaucoma
Interventions
IRX-101, Control
Drug
Lead sponsor
iRenix Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 28, 2026, 8:28 AM EDT
Recruiting Not applicable Interventional

Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver

NCT07364474
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Melphalan through Percutaneous Hepatic Perfusion, Melphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 8:28 AM EDT
Completed No phase listed Observational

Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma

NCT04458935
View directory record Official record
Conditions
Retinal Hemangioblastoma, Von Hippel-Lindau Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
7 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 28, 2026, 8:28 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Ocular Proteomics Testing In Chronic Atrophy

NCT07298291
View directory record Official record
Conditions
Age-Related (Dry) Macular Degeneration
Interventions
AC Tap (anterior chamber paracenthesis)
Procedure
Lead sponsor
ClinOmicsAI
Network
Eligibility
50 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 28, 2026, 8:28 AM EDT
Completed Phase 3 Interventional Results available

Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery

NCT01230125
View directory record Official record
Conditions
Cataract
Interventions
Mapracorat, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 28, 2026, 8:28 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Alaska Oculocardiac Reflex Study

NCT04353960
View directory record Official record
Conditions
Bradycardia, Strabismus
Interventions
electrocardiograph
Diagnostic Test
Lead sponsor
Alaska Blind Child Discovery
Other
Eligibility
1 Month to 100 Years
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2035
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 28, 2026, 8:28 AM EDT
Recruiting Phase 4 Interventional

Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects

NCT04401982
View directory record Official record
Conditions
Ocular Hypertension, Suspect Glaucoma
Interventions
Rocklatan (Netarsudil 0.02%/ latanoprost 0.005), Latanoprost (0.005%)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Columbia, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 28, 2026, 8:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid

NCT00584935
View directory record Official record
Conditions
Ocular Cicatricial Pemphigoid
Interventions
Rituximab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 28, 2026, 8:28 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Statistical Learning as a Novel Intervention for Cortical Blindness

NCT06578117
View directory record Official record
Conditions
Stroke, Ischemic, Hemianopia, Homonymous, Hemianopsia, Occipital Lobe Infarct, Visual Field Defect, Peripheral, Vision Loss Partial, Quadrantanopia, Stroke Hemorrhagic
Interventions
Vision Training and Learning Task
Device
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 8:28 AM EDT
Recruiting Phase 4 Interventional

Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency

NCT07502378
View directory record Official record
Conditions
Ocular Surface Disease, Neurotrophic Keratopathy Stage 1
Interventions
Patients will receive topical Acoltremon 0.003% ophthalmic solution BID in both eyes over an 8 week period., Alternative would be patient exiting the trial and starting on tears or other standard of care.
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 28, 2026, 8:28 AM EDT
Completed Phase 4 Interventional Results available

Visual Function After Implantation of Bilateral AcrySof® Toric Natural Intraocular Lens

NCT00760487
View directory record Official record
Conditions
Cataract
Interventions
AcrySof Toric IOL
Device
Lead sponsor
Alcon Research
Industry
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2012 · Synced Oct 28, 2026, 8:28 AM EDT
Completed Not applicable Interventional Results available

The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction

NCT01207752
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Systane Balance, Optive Lubricant Eye Drops
Drug
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 28, 2026, 8:28 AM EDT